obecabtagene autoleucel
Cell therapyapprovedOrphan Drug FDA
Approved
Nov 8, 2024
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 2, 2024 (NCT06333483)
Timeline
Indications
Approved for
Mechanism of action
- B-lymphocyte antigen CD19BINDING AGENT
B-lymphocyte antigen CD19 binding agent
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Approval history
- approvedNov 8, 2024
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Black box warning
Sources
- ChEMBLCHEMBL5095440 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07053800 | Phase 2 | Sep 30, 2025 | Autolus Limited, PPD |
| NCT07053059 | Phase 2 | Aug 26, 2025 | University of Texas at Houston |
| NCT07139743 | Phase 1 | Aug 4, 2025 | Autolus Limited |
| NCT06333483 | Phase 1 | Feb 2, 2024 | Autolus Limited |
| NCT06799221 | N/A | — | Autolus Limited, IQVIA |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Autolus Limited | For profit | 4 | 4 | 3 | 2024 |
| IQVIA | For profit | 1 | 0 | 1 | — |
| PPD | For profit | 1 | 0 | 1 | 2025 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1